Critical Contrast: Generate Biomedicines (NASDAQ:GENB) vs. iBio (NASDAQ:IBIO)

Generate Biomedicines (NASDAQ:GENB – Get Free Report) and iBio (NASDAQ:IBIO – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Profitability

This table compares Generate Biomedicines and iBio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Generate Biomedicines -1,289.97% -151.21% -54.73%
iBio N/A -40.05% -35.35%

Institutional and Insider Ownership

7.9% of iBio shares are held by institutional investors. 1.5% of iBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Generate Biomedicines and iBio, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Generate Biomedicines 1 1 6 0 2.62
iBio 1 0 4 2 3.00

Generate Biomedicines presently has a consensus target price of $26.20, indicating a potential upside of 174.63%. iBio has a consensus target price of $6.00, indicating a potential upside of 631.71%. Given iBio’s stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Generate Biomedicines.

Earnings and Valuation

This table compares Generate Biomedicines and iBio”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Generate Biomedicines $31.89 million 38.62 -$203.15 million ($2.27) -4.20
iBio $100,000.00 577.77 -$33.04 million ($0.28) -2.93

iBio has lower revenue, but higher earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Summary

iBio beats Generate Biomedicines on 11 of the 13 factors compared between the two stocks.

About Generate Biomedicines

(Get Free Report)

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and experimental biology to design and develop medicines. Founded in 2018 by Flagship Pioneering, the company is based in Somerville, Massachusetts. Its platform is designed to create new proteins with potential therapeutic applications, including antibodies and other biologic medicines. Generate is advancing a drug-development pipeline across areas such as immunology and oncology; one of its candidates, GB-0895, is being developed for asthma.

About iBio

(Get Free Report)

iBio, Inc. is a biotechnology company focused on using artificial intelligence and other computational tools to discover and develop therapies. Its research has included programs targeting obesity and metabolic diseases, as well as oncology. The company’s current approach builds on its earlier work in biologics manufacturing. Historically, iBio used its plant-based FastPharming platform to produce proteins and antibodies for research and therapeutic development. iBio is based in the United States and has shifted its focus from plant-based biologics production toward AI-enabled drug discovery.

Receive News & Ratings for Generate Biomedicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generate Biomedicines and related companies with MarketBeat.com's FREE daily email newsletter.